نتائج البحث 21-30 من 2500 لعملية البحث عن Inhibition
This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...
To explore if response to checkpoint inhibitors is dependent on biomarkers on tumor tissue. MElanoma Research Lymph node prediction Implementation ...
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus ...
Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Frontiers in Pharmacology. 2016; doi:10.3389/fphar.2016.00340. Thomas SJ, et al. Combination ...
... inhibitor. In the phase II part, to evaluate the preliminary antitumor activity of two different doses/regimens of [177Lu]Lu-NeoB in combination with ...
Olaparib is an inhibitor of PARP, an enzyme that helps repair ... PARP inhibitors are a type of targeted therapy. Adding abemaciclib to ...
... inhibitors and are refractory to or intolerant to other available therapies. Biorepository for Acute Leukemia Research. Rochester, Minn. The purpose of this ...
The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®). Tissue ...
... inhibitors sirolimus or everolimus as part of their clinical care. Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now.
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.